Hennion & Walsh Asset Management Inc. Acquires 2,094 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Hennion & Walsh Asset Management Inc. lifted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 80.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 4,696 shares of the medical research company's stock after acquiring an additional 2,094 shares during the quarter. Hennion & Walsh Asset Management Inc.'s holdings in Thermo Fisher Scientific were worth $2,443,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Legacy Investment Solutions LLC purchased a new stake in shares of Thermo Fisher Scientific during the third quarter valued at approximately $26,000. Peterson Financial Group Inc. bought a new stake in Thermo Fisher Scientific during the 3rd quarter valued at $27,000. RPg Family Wealth Advisory LLC purchased a new position in shares of Thermo Fisher Scientific in the third quarter valued at about $50,000. HWG Holdings LP bought a new position in shares of Thermo Fisher Scientific during the second quarter valued at about $50,000. Finally, Teachers Insurance & Annuity Association of America bought a new stake in shares of Thermo Fisher Scientific in the third quarter worth about $65,000. Institutional investors own 89.23% of the company's stock.

Analyst Ratings Changes

Several research firms have weighed in on TMO. TD Cowen increased their price objective on Thermo Fisher Scientific from $656.00 to $686.00 in a report on Tuesday, October 22nd. Wells Fargo & Company dropped their price target on Thermo Fisher Scientific from $670.00 to $660.00 and set an "overweight" rating for the company in a research note on Thursday, October 24th. Redburn Atlantic started coverage on shares of Thermo Fisher Scientific in a report on Monday, October 14th. They issued a "buy" rating and a $680.00 price objective for the company. Morgan Stanley cut their target price on shares of Thermo Fisher Scientific from $670.00 to $647.00 and set an "overweight" rating on the stock in a research note on Monday, January 13th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an "overweight" rating in a report on Friday, September 20th. Four investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $648.95.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $554.29, for a total value of $5,542,900.00. Following the completion of the sale, the chief executive officer now owns 121,192 shares in the company, valued at $67,175,513.68. This represents a 7.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $1,120,320.00. Following the transaction, the senior vice president now directly owns 12,736 shares in the company, valued at approximately $7,134,197.76. The trade was a 13.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 47,150 shares of company stock worth $25,954,465 in the last three months. 0.34% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Down 0.4 %

Shares of TMO traded down $1.99 on Friday, hitting $559.72. 2,134,669 shares of the stock traded hands, compared to its average volume of 1,426,114. The company has a market capitalization of $214.09 billion, a PE ratio of 35.09, a P/E/G ratio of 3.59 and a beta of 0.76. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The business has a 50 day simple moving average of $529.96 and a 200 day simple moving average of $568.09.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating analysts' consensus estimates of $5.25 by $0.03. The company had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The firm's revenue for the quarter was up .2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $5.69 earnings per share. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.28%. The ex-dividend date of this dividend was Friday, December 13th. Thermo Fisher Scientific's dividend payout ratio is 9.78%.

Thermo Fisher Scientific declared that its board has authorized a share buyback program on Friday, November 15th that permits the company to repurchase $4.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 2% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's board of directors believes its stock is undervalued.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.